News Release

膀胱药物与动脉粥样硬化

Peer-Reviewed Publication

Proceedings of the National Academy of Sciences

科研人员报告说，一种已经批准用于膀胱疾病的药物米拉贝隆能增加动脉粥样硬化小鼠模型的胆固醇合成，导致血清低密度脂蛋白（LDL）以及超低密度脂蛋白（VLDL）胆固醇水平的增加，以及动脉粥样硬化斑块生长加速；这些变化取决于产热作用脂肪分解，这也是由米拉贝隆疗法诱导产生的，这提示米拉贝隆可能增加心血管和脑血管疾病风险，特别是对于拥有LDL受体突变的病人。

###

Journal

Proceedings of the National Academy of Sciences

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.